huPBMC-(MHCII/B2M-KO NMG)

Nomenclature

huPBMC-NOD.Cg-PrkdcscidIl2rgem1H2-Ab1em1H2-Aaem1H2-Eb1em1H2-Eb2em1H2-Ea-ps em1B2mem1Smoc

Cat. NO.

NM-HU-263012

Strain State

Repository Live

Export PDF

Model Description

MHCII and B2m genes were knocked out on NMG mice. An immune reconstitution model was constructed by transplanting fresh human peripheral blood mononuclear cells (PBMCs) into MHCII/B2M-KO(NMG) mice. This model exhibits a low degree of graft-versus-host disease (GvHD).

Validation Data

image.png

Fig 1. Body weight growth curve, survival rate and GvHD scores of huPBMC-MHC2/B2m-dKO(NMG) mice. 

image.png

Fig 2. Flow cytometry analysis of peripheral blood lymphocyte subpopulations in the huPBMC-MHC2/B2m-dKO(NMG) mouse model. Human PBMCs (1E7) were injected intravenously (female, 6-8 weeks old, n=8). Blood from mice at different time points after implantation of human PBMCs was taken for flow cytometry analysis.

image.png

Fig 3. Efficacy evaluation of BiTE in huPBMC-MHC2/B2m-dKO(NMG) model of small cell lung cancer.

image.png

Fig 4. Efficacy evaluation of BiTE in huPBMC-MHCII/B2M-dKO(NMG) model of lymphoblastic leukemia.

image.png

Fig 5. Efficacy evaluation of anti-PD1 Ab in huPBMC-MHCII/B2M-dKO(NMG) model of malignant melanoma.

image.png

Fig 6. Efficacy evaluation of anti-CD3 Ab in huPBMC-MHCII/B2M-dKO(NMG) model of lymphoblastic leukemia.

image.png

Fig 7. Efficacy evaluation in huPBMC-MHCII/B2M-dKO(NMG) model of liver cancer.

image.png

Fig8. Efficacy evaluation of in vivo CAR-T cell therapy in huPBMC-MHCII/B2M-dKO (NMG) model of lymphoblastic leukemia


For strain background verification data, refer to MHCII/B2m-KO(NMG) NM-NSG-014. Click the link below for more details:

MHCII/B2m-KO(NMG)-SMOC


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more

Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more